1-3 of 3
Paul A. Foster, MD
Close
Sort by
Journal Articles

Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Jennifer A. Woyach, MD, Farrukh Awan, MD MS, Ian Flinn, Jesus G. Berdeja, MD, Elizabeth A Wiley, Sharmeen Mansoor, Ying Huang, MA, MS, Gerard Lozanski, MD, Paul A. Foster, MD, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 1993.
https://doi.org/10.1182/blood.V124.21.1993.1993
Published: 2014
Journal Articles

Final Results of a Phase I Study of the Fc Engineered CD19 Antibody XmAb®5574 (MOR00208) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

Jennifer A. Woyach, MD, Farrukh Awan, MD, MS, Ian W. Flinn, MD, PhD, Rolondo Enoch, MS, Paul A. Foster, MD, John C. Byrd, MD
Journal: Blood
Blood (2012) 120 (21): 2894.
https://doi.org/10.1182/blood.V120.21.2894.2894
Published: 2012
Journal Articles

Incidence of Altered Biodistribution Detected by Indium 111 ( 111 In) Imaging Prior to Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy: Results from a Zevalin Imaging Registry.

Peter Conti, MD, Christine White, MD, Peter Pieslor, MD, Gene Menendez, V. Douglas Harrough, MS, MBA, Dan Matso, PharmD, Jacqueline Aussie, Thomas Ryskamp, Paul A. Foster, MD
Journal: Blood
Blood (2004) 104 (11): 4570.
https://doi.org/10.1182/blood.V104.11.4570.4570
Published: 2004